WITHDRAWN: Oral sumatriptan for acute migraine

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Migraine is a prevalent neurovascular disorder causing severe headaches and autonomic dysfunction.
• Sumatriptan, a selective serotonin 5-HT1B/1D agonist, targets migraine pathophysiology through cranial vasoconstriction and neural inhibition.

Purpose of the Study:

• To evaluate the efficacy and tolerability of oral sumatriptan for acute migraine attacks in adults.
• Assessment based on evidence from randomized controlled trials (RCTs).

Main Methods:

• Systematic review of double-blind RCTs comparing oral sumatriptan (25-100 mg) with placebo or other interventions.
• Searched Cochrane Central Register, MEDLINE, and reference lists.
• Analyzed outcomes including pain-free response, headache relief, functional disability, and adverse events.

Main Results:

• Sumatriptan (100 mg and 25 mg) significantly improved pain-free response, headache relief, and functional disability at 2 hours compared to placebo.
• Number-needed-to-treat (NNT) for pain-free response at 2 hours was 5.1 for 100 mg sumatriptan.
• Adverse events were more frequent with 100 mg sumatriptan (NNH=7.1) than placebo, though generally minor.

Conclusions:

• Oral sumatriptan is an effective treatment for acute migraine attacks.
• The drug is generally well-tolerated, with minor adverse events being common.
• Sumatriptan demonstrated superior efficacy compared to ergotamine + caffeine.